SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial
10 references·0 citing·50 second hop
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial (2019)Cost Effectiveness of Interval Cytoreduct…Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement (2018)Review and critical appraisal…Discounting in Economic Evaluations (2018)Discounting in Economic Evalu…On the Estimation of the Cost-Effectiveness Threshold: Why, What, How? (2016)On the Estimation of the Cost…Dutch Tariff for the Five-Level Version of EQ-5D (2016)Dutch Tariff for the Five-Lev…Cost–effectiveness thresholds: pros and cons (2016)Cost–effectiveness thresholds…Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Survival Analysis for Economi…Healthcare Rationing by Proxy (2010)Healthcare Rationing by ProxyGood Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II (2009)Good Research Practices for M…Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment (2009)Determination of quality of l…Generalized cost-effectiveness analysis for national-level priority-setting in the health sector (2003)Generalized cost-effectivenes…The General Theory of Second Best (1956)Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Research trends in contemporary health economics: a scientometric analysis on collective content of specialty journals (2024)Methods for the economic evaluation of health care programmes (1987)Cost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events (2013)Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada (2016)Population Genomic Screening for Three Common Hereditary Conditions (2023)Decision Modelling For Health Economic Evaluation (2006)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Planning for Long-Term Follow-Up: Strategies Learned from Longitudinal Studies (2015)Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling (2016)Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? (2020)Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness (1995)A framework for assessing the performance of health systems. (2000)Making choices in health: who guide to cost-effectiveness analysis (2004)Cost-Effectiveness Thresholds: the Past, the Present and the Future (2018)Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies (2018)Eliciting and Utilizing Willingness to Pay: Evidence from Field Trials in Northern Ghana (2019)Modeling Valuations for EuroQol Health States (1997)Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) (2011)Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study (2012)Estimating an EQ-5D-5L Value Set for China (2017)Discrete Choice Experiments in Health Economics: Past, Present and Future (2018)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)The Future of Precision Medicine: Potential Impacts for Health Technology Assessment (2018)Calculating and Interpreting ICERs and Net Benefit (2020)Understanding the global measurement of willingness to pay in health (2020)Global health 2035: a world converging within a generation (2013)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations (2021)Quantifying the global burden of mental disorders and their economic value (2022)A Contribution to the Theory of Taxation (1927)Social Costs of Monopoly and Regulation (1974)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets (2012)Valuing health-related quality of life: An EQ-5D-5L value set for England (2017)Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis (2019)Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer (2020)Value Sets for EQ-5D-5L (2022)US Environmental Protection Agency (1998)Time Discounting and Time Preference: A Critical Review (2002)When is it too expensive? Cost-effectiveness thresholds and health care decision-making (2018)Adjusting for Inflation and Currency Changes Within Health Economic Studies (2019)On discount rates for economic evaluations in global health (2019)
this work references cited by second hop

References

  • 2016Dutch Tariff for the Five-Level Version of EQ-5D1,110 cited
  • 2016Cost–effectiveness thresholds: pros and cons789 cited
  • 2013Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data541 cited
  • 2003Generalized cost-effectiveness analysis for national-level priority-setting in the health sector535 cited
  • 2018Discounting in Economic Evaluations350 cited
  • 2009Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II203 cited
  • 2016On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?170 cited
  • 2009Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment126 cited
  • 2018Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement120 cited
  • 2010Healthcare Rationing by Proxy72 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work